Drugs / BoNT-A
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05411900 | May 2022 → Dec 2023 | carpal tunnel syndrome, neuropathy, painful | Francesco Bono | Unknown | No outcome recorded |
| Phase 2 | NCT02427646 | Oct 2011 → Apr 2015 | movement disorder | Western University, Canada | Unknown | Met primary |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT01275521 | Jan 2011 → Apr 2015 | benign prostatic hyperplasia | University Hospital, Bordeaux | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02505802 | Jan 2014 → Jan 2017 | stroke disorder | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06225024 | Mar 2022 → Jun 2023 | stroke disorder | Kayseri City Hospital | Completed | No outcome recorded |
| — | NCT07426640 | Nov 2021 → Nov 2024 | premature ejaculation | Al Mouwasat Hospital | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-11 | Galderma R&D | Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe galderma.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BoNT-A | “Botulinum Neurotoxin Type A (BoNT-A) prostatic injection” PMID 29383480 ↗ Jan 2018 |
| Known as | Botulinum Neurotoxin Type A | “Botulinum Neurotoxin Type A (BoNT-A) prostatic injection” PMID 29383480 ↗ Jan 2018 |
| Known as | botulinum toxin A | “Data from previous studies suggest that botulinum toxin A has analgesic effects against peripheral neuropathic pain, but the quality of the evidence is low.” PMID 26947719 ↗ Mar 20161“Botulinum toxin A” NCT02505802 ↗ |
| Known as | Botulinum toxin type A | “Botulinum toxin type A (BoNT-A) is widely used to treat muscle hyperactivity, based on its ability to inhibit synaptic exocytosis and, therefore, to disable neural transmission.” NCT05411900 ↗1“Botulinum toxin type A was injected into the bulbospongiosus muscle and glans penis according to a standerdized protocol.” NCT07426640 ↗ |
| Known as | BTX-A | “Botulinum toxin type A (BTX-A) has been reported to have analgesic effects independent of its action on muscle tone, possibly by acting on neurogenic inflammation.” PMID 18546285 ↗ Sep 2008 |
| Action | Inhibit | “BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction.” NCT02427646 ↗ |
| Modality | Protein / enzyme biologic | “Botulinum Neurotoxin Type A (BoNT-A) prostatic injection” PMID 29383480 ↗ Jan 2018 |
| Route | Other | “BoNT-A injection consisted in trans-rectal injections of 200 UI in the transitional zone of the prostate.” PMID 29383480 ↗ Jan 2018 |
| Target | SNAP25 | “specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25)” NCT02427646 ↗ |